These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 18163969)

  • 1. Evaluation of C-reactive protein in primary and secondary prevention.
    Corrado E; Novo S
    J Investig Med; 2007 Dec; 55(8):430-8. PubMed ID: 18163969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy.
    Koenig W
    Int J Cardiol; 2013 Oct; 168(6):5126-34. PubMed ID: 23978367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [High sensitivity of C-reactive protein in primary prevention].
    Corrado E; Novo S
    G Ital Cardiol (Rome); 2007 Jun; 8(6):327-34. PubMed ID: 17633905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S; Ridker PM
    Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Critical appraisal of inflammatory markers in cardiovascular risk stratification.
    Krintus M; Kozinski M; Kubica J; Sypniewska G
    Crit Rev Clin Lab Sci; 2014 Oct; 51(5):263-79. PubMed ID: 24918900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship of C-reactive protein, metabolic syndrome and diabetes mellitus: potential role of statins.
    Nash DT
    J Natl Med Assoc; 2005 Dec; 97(12):1600-7. PubMed ID: 16396052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of C-reactive protein in cardiovascular disease.
    Backes JM; Howard PA; Moriarty PM
    Ann Pharmacother; 2004 Jan; 38(1):110-8. PubMed ID: 14742804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale for targeted rather than population based screening with C-reactive protein using the National Health and Nutrition Examination Survey (1999 to 2002).
    Guttormsen BN; Stein JH; McBride PE; Cullen MW; Gangnon R; Keevil JG
    Am J Cardiol; 2007 Oct; 100(7):1130-3. PubMed ID: 17884376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-sensitivity C-reactive protein, inflammation, and cardiovascular risk: from concept to clinical practice to clinical benefit.
    Ridker PM
    Am Heart J; 2004 Jul; 148(1 Suppl):S19-26. PubMed ID: 15211329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sex related cardiovascular risk stratification based on quantification of atherosclerosis and inflammation.
    Erbel R; Möhlenkamp S; Lehmann N; Schmermund A; Moebus S; Stang A; Grönemeyer D; Seibel R; Mann K; Volbracht L; Dragano N; Siegrist J; Jöckel KH;
    Atherosclerosis; 2008 Apr; 197(2):662-72. PubMed ID: 17386928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C-reactive protein: a new risk assessment tool for cardiovascular disease.
    Clearfield MB
    J Am Osteopath Assoc; 2005 Sep; 105(9):409-16. PubMed ID: 16239491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases.
    Li JJ; Fang CH
    Med Hypotheses; 2004; 62(4):499-506. PubMed ID: 15050096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of C-reactive protein in coronary risk reduction: focus on primary prevention.
    Gotto AM
    Am J Cardiol; 2007 Mar; 99(5):718-25. PubMed ID: 17317380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [C-reactive protein in cardiovascular risk evaluation].
    Fabijanić D; Banić M; Kardum D
    Lijec Vjesn; 2006; 128(5-6):167-74. PubMed ID: 16910418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting risk and treatment benefit in atherosclerosis: the role of C-reactive protein.
    Koenig W
    Int J Cardiol; 2005 Feb; 98(2):199-206. PubMed ID: 15686768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C-reactive protein: risk assessment in the primary prevention of atherosclerotic disease. Has the time come for including it in the risk profile?
    Koenig W
    Ital Heart J; 2001 Mar; 2(3):157-63. PubMed ID: 11305526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).
    Ridker PM; MacFadyen JG; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
    Circ Cardiovasc Qual Outcomes; 2009 Nov; 2(6):616-23. PubMed ID: 20031900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link?
    Yousuf O; Mohanty BD; Martin SS; Joshi PH; Blaha MJ; Nasir K; Blumenthal RS; Budoff MJ
    J Am Coll Cardiol; 2013 Jul; 62(5):397-408. PubMed ID: 23727085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment.
    Libby P; Ridker PM
    Am J Med; 2004 Mar; 116 Suppl 6A():9S-16S. PubMed ID: 15050187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C-reactive protein: a novel marker of cardiovascular risk.
    Shah SH; Newby LK
    Cardiol Rev; 2003; 11(4):169-79. PubMed ID: 12852794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.